These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 8780403

  • 1. Immunohistochemical study of DNA topoisomerase II in human gastric disorders.
    Yabuki N, Sasano H, Kato K, Ohara S, Toyota T, Nagura H, Miyaike M, Nozaki N, Kikuchi A.
    Am J Pathol; 1996 Sep; 149(3):997-1007. PubMed ID: 8780403
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunohistochemistry of Caspase3/CPP32 in human stomach and its correlation with cell proliferation and apoptosis.
    Hoshi T, Sasano H, Kato K, Yabuki N, Ohara S, Konno R, Asaki S, Toyota T, Tateno H, Nagura H.
    Anticancer Res; 1998 Sep; 18(6A):4347-53. PubMed ID: 9891491
    [Abstract] [Full Text] [Related]

  • 5. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K.
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
    Kim R, Ohi Y, Inoue H, Toge T.
    Anticancer Res; 1999 May; 19(6B):5393-8. PubMed ID: 10697567
    [Abstract] [Full Text] [Related]

  • 10. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K.
    Hepatogastroenterology; 2008 May; 55(86-87):1530-6. PubMed ID: 19102336
    [Abstract] [Full Text] [Related]

  • 11. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
    Villman K, Ståhl E, Liljegren G, Tidefelt U, Karlsson MG.
    Mod Pathol; 2002 May; 15(5):486-91. PubMed ID: 12011253
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
    Coleman LW, Bronstein IB, Holden JA.
    Anticancer Res; 2001 May; 21(2A):1167-72. PubMed ID: 11396158
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, Cho J, Adler H, Dar K, Zeleniuch-Jacquotte A, Hochster H.
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [Abstract] [Full Text] [Related]

  • 14. Topoisomerase II alpha expression in normal, inflammatory, and neoplastic conditions of the gastric and colonic mucosa.
    Fogt F, Nikulasson ST, Holden JA, Alder SA, Hallgrimsson J, Jessup MJ, O'Brien MJ, Lavin PT, Goldman H.
    Mod Pathol; 1997 Apr; 10(4):296-302. PubMed ID: 9110290
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase II levels during granulocytic maturation in vitro and in vivo.
    Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ.
    Cancer Res; 1991 Jul 01; 51(13):3534-43. PubMed ID: 1647269
    [Abstract] [Full Text] [Related]

  • 16. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS.
    Mod Pathol; 2000 May 01; 13(5):542-7. PubMed ID: 10824926
    [Abstract] [Full Text] [Related]

  • 17. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S, Chatterjee S, Ranjit GB, Bao C, Ford J, Ganapathi R, Berger SJ, Berger NA.
    Oncol Res; 1995 May 01; 7(7-8):407-16. PubMed ID: 8747604
    [Abstract] [Full Text] [Related]

  • 18. Tissue microarray analysis of topoisomerase IIalpha protein in gastric adenocarcinomas: histogenetic and prognostic implications.
    Wang G, Huang H, Gao J, Chen P, You W, Wu B, Wang M.
    Cancer Genomics Proteomics; 2011 May 01; 8(3):127-33. PubMed ID: 21518818
    [Abstract] [Full Text] [Related]

  • 19. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW, Mirski SE, Cole SP, Sullivan DM.
    Cancer Res; 1994 Feb 01; 54(3):756-62. PubMed ID: 8306338
    [Abstract] [Full Text] [Related]

  • 20. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
    Stathopoulos GP, Kapranos N, Manolopoulos L, Papadimitriou C, Adamopoulos G.
    Anticancer Res; 2000 Feb 01; 20(1A):177-82. PubMed ID: 10769652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.